Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 23 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 FDA Approves Pembrolizumab with Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma MOST POPULAR New Drugs, New Side Effects: Complications of Cancer Immunotherapy May 10, 2019 ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... June 6, 2023 5-Yr-Old Has Cutest Celebration With Big Brother After Being Declared Cancer-Free. May 21, 2019 I Received the COVID-19 Vaccine – Now What? February 8, 2021 Load more HOT NEWS The art of practicing sustainable science ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... Two-Time Breast Cancer Warrior Left Devastated After Package Full of Meds... ESMO Immuno-Oncology Congress 2023, 6-8 December 2023, Geneva, Switzerland
